ПРИМЕНЕНИЕ ЦЕРТОЛИЗУМАБА ПЭГОЛА ПРИ БОЛЕЗНИ КРОНА (обзор литературы)

болезнь Крона, цертолизумаб пэгол

1. Wilkins T., Jarvis K., Patel J. Diagnosis and management of Crohn’s disease. Am. Fam. Physician. - 2011; 84: 1365-75.

2. Behm B.W., Bickston S.J. Tumor necrosis factoralpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. -2008; (1): CD006893.

3. Rivkin A. Certolizumab pegol for the management of Crohn’s disease in adults. Clin. Ther. - 2009; 31: 1158-76.

4. Tracey D., Klareskog L., Sasso E.H. et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. - 2008 Feb; 117 (2): 244-79.

5. Reichert J.M. Which are the antibodies to watch in 2013? MAbs. - 2013 Jan-Feb; 5 (1): 1-4.

6. Schreiber S. Certolizumab pegol for the treatment of Crohn’s disease. Therap Adv Gastroenterol. - 2011 Nov; 4 (6): 375-89.

7. Fleischmann R., Shealy D. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis. Mol. Interv. - 2003; 3: 310-8.

8. Weir N., Athwal D., Brown D. et al. A new generation of high-affinity humanized PEGylated Fab’ fragment anti-tumour necrosis factor-a monoclonal antibodies. Therapy. - 2006; 3: 535-45.

9. Nesbitt A., Fossati G., Bergin M. et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumour necrosis factor a agents. - 2007; 13: 1323-32.

10. Gramlick G., Fossati G., Nesbitt A. et al. Neutralization of soluble and membrane tumour necrosis factor a by infliximab, adalimumab or certolizumab pegol using p55 or p75 TNFa receptor bioassay. Gastroenterology. -2006; 130: 697.

11. Stephens S., Brown D., Nesbitt A. et al. Lack of placental transfer and accumulation in milk of an anti-TNF PEGylated Fab’. - 2007; 1: 43.

12. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today. - 2005; 10: 1451-8.

13. Chapman A.P. PEGylated antibodies and antibody fragments for improved therapy: Rev. - 2002; 54: 531-45.

14. Chapman A.P., Antoniw P., Spitali M. et al. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. - 1999; 17: 780-3.

15. Parton T., King L., van Asperen J. et al. Investigation of the distribution and elimination of the PEG component of certolizumab. J. Crohn’s Colitis. - 2008; 2: 26.

16. Parton T., King L., Parker G. et al. The PEG moiety of certolizumab pegol is rapidly cleared from the blood of humans by the kidneys once it is cleaved the Fab’. Ann. Rheum Dis. - 2009; 68: 189.

17. Sandborn W.J., Feagan B.G., Stoinov S. et al. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med. - 2007; 357: 228-38.

18. Schreiber S., Khaliq-Kareemi M., Lawrance I.C. et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med. - 2007; 537: 239-50.

19. Lichenstien G., Thomsen O., Schreiber S. et al. Long-term remission with certolizumab pegol in Crohn’s disease over 3,5 years: results from the PRECiSE 3 study. Gastroenterol. - 2009; 104: 450.

20. Sandborn W., Schreiber S., Hanauer S. et al. Longterm maintenance of remission with no dose escalation after reinduction with certolizumab pegol in patients with Crohn’s disease exacerbation: 3-year results from the PRECiSE 4 Study. Am. J. Gastroenterol. - 2009; 104: 448.

21. Blonski W., Lichtenstein G.R. Safety of biologics in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. - 2006a; 9: 221-233.

22. Winter T.A., Wright J., Ghosh S. et al. Intravenous CDP870, a pegylated Fab’ fragment of a humanized antitumor necrosis factor antibody, in patients with moderate to severe Crohn’s disease: an exploratory study. Aliment. Pharmacol. Ther. - 2004; 20: 1337-1346.

23. Schreiber S., Rutgeerts P., Fedorak R.N. et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. - 2005a; 129: 807-818.

24. Schreiber S., Feagan B.G., Hanauer S.B. et al. Subcutaneous certolizumab pegol is well tolerated by patients with active Crohn’s disease: results from two phase III studies (PRECISE 1 and 2). J. Crohn’s Colitis. -2007a; 1: 9. Abstract P021.

25. Fefferman D.S., Farrell R.J. Immunogenicity of biological agents in inflammatory bowel disease. Inflamm. Bowel Dis. - 2005; 11: 497-503.

26. Van Assche G., Vermeire S., Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr. Opin. Gastroenterol. - 2006; 22: 370-376.

27. Choy E.H., Hazleman B., Smith M. et al. Efficacy of a novel pegylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology. - 2002; 41: 1133-1137.

28. Schreiber S., Khaliq-Kareemi M., Lawrence I.C. et al. Certolizumab pegol, a humanised anti-TNF pegylated Fab’ fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn’s disease: a phase III study (PRECiSE 2). Gut. -2005b; 54 (Suppl. VII). Abstract 82.

29. Vetterlein O.M., Kopotsha T., Nesbitt A.M. et al. Antibodies to infliximab in patients with Crohn’s disease do not cross-react with certolizumab pegol. Gut. - 2006; 55 (Suppl. V): A133. Abstract MON-G-261.

30. Vetterlein O.M., Nesbitt A.M., Stephens S. Antibodies to certolizumab pegol in patients with Crohn’s disease do not cross-react with adalimumab, etanercept, or infliximab. Gastroenterology. - 2007; 132: 4 (Suppl. 2): A-556. Abstract T1784.

31. Hanauer S.B., Feagan B.G., Lichtenstein G.R. et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. - 2002; 359: 1541-1549.

32. Colombel J.F., Sandborn W.J., Rutgeerts P. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. - 2007; 132: 52-65.

33. Schreiber S., Rutgeerts P., Fedorak R.N. et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. - 2005; 129: 807-818.

34. Sandborn W.J., Abreu M.T., D’Haens G. et al. Certolisumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximab. Clin Gastr Hepatol. - 2010; 8: 688-695.

35. Felley C., Mottet C., Juillerat P. et al. Fistulizing Crohn’s disease. - 76: 109-12.

36. Schwartz D.A., Loftus E.V. Jr., Tremaine W.J. et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. - 2002; 122: 875-80.

37. Kamm M.A., Ng S.C. Perianal fistulizing Crohn’s disease: a call to action. Clin. Gastroenterol. Hepatol. -2008; 6: 7-10.

38. Nielsen O.H., Rogier G., Hahnloser D. et al. Diagnosis and management of fistulizing Crohn’s disease. Nat Clin. Pract. Gastroenterol. Hepatol. - 2009; 6: 92-106.

39. Judge T. A., Lichtenstein G. R. Treatment of fistulizing Crohn’s disease. Gastroenterol. Clin. North. Am. - 2004; 33: 421-54.

40. Sandborn W.J., Fazio V.W., Feagan B.G. et al. AGA technical review on perianal Crohn’s disease. Gastroenterology. - 2003; 125: 1508-30.

41. Peyrin-Biroulet L., Deltenre P., de Suray N. et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. - 2008; 6: 644-53.

42. Schreiber S., Lawrance I.C., Thomsen O.Ө. et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebocontrolled study. Aliment Pharmacol. Ther. - 2011 Jan; 33 (2): 185-93.

43. Present D.H., Rutgeerts P., Targan S. etal. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med. - 1999; 340: 1398-405.

44. Sands B.E., Anderson F.H., Bernstein C.N. et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med. - 2004; 350: 876-85.

45. Ostensen M., Förger F. Management of RA medications in pregnant patients. Nat. Rev. Rheumatol. -2009; 5: 382-90.

46. Marchioni R.M., Lichtenstein G.R. Tumor necrosis factor-а inhibitor therapy and fetal risk: a systematic literature review. World J. Gastroenterol. -2013; 19: 2591-602.

47. Mahadevan U., Cucchiara S., Hyams J.S. et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am. J. Gastroenterol. - 2011; 106: 214-23.

48. Baker T., Kevorkian L., Nesbitt A. Investigation into the binding affinity of certolizumab pegol to FcRn and functional consequences for FcRn-mediated transcytosis: Comparison to infliximab, adalimumab and etanercept. Ann. Rheum. Dis. - 2013; 72 Suppl. 3: 426.

49. Mahadevan U., Wolf D.C., Dubinsky M. et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. - 2013; 11: 286-92.

50. Porter C., Kopotsha T., Smith B. et al. No significant transfer of certolizumab pegol compared with IgG in the perfused human placenta in vitro. Ann. Rheum. Dis. - 2010; 69 Suppl 3: 210.

51. Brown D., Nesbitt A., Stephens S. et al. Lack of placental transfer and accumulation in milk of an anti-TNF PEGylated Fab’ fragment in rats: P-0030. Inflamm. Bowel Dis. - 2007; 13: 656.

52. Götestam Skorpen C. et al. Ann Rheum Dis 2016; 0: 1-16. doi: 10.1136/annrheumdis-2015-208840

53. Clowse M.E., Wolf D.C., Forger F. et al. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol. J. Rheumatol. - 2015 Dec; 42 (12): 2270-8.